Since experimental studies have shown that PD-L1 expression in early breast cancer is associated with higher T-cell infiltration, we assume that PD-L1-negative tumour cells are able to inhibit effector T cells by either the physical barrier of breast TME or non-PD-1/PD-L1 suppression pathways [40–42]. This evidence concerns the gene CD274 and breast carcinoma.